Keros Therapeutics, Inc. Common Stock (KROS) is a publicly traded Healthcare sector company. As of May 21, 2026, KROS trades at $10.98 with a market cap of $201.09M and a P/E ratio of 4.57. KROS moved +11.10% today. Year to date, KROS is -38.73%; over the trailing twelve months it is -22.35%. Its 52-week range spans $9.12 to $72.37. Analyst consensus is buy with an average price target of $21.20. Rallies surfaces KROS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes KROS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $10.98 |
| Market Cap | $201.09M |
| P/E Ratio | 4.57 |
| EPS | $2.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $72.37 |
| 52-Week Low | $9.12 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $243.86M |
| Net Income | $87.01M |
| Gross Margin | 0.00% |
8 analysts cover KROS: 0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.20.